TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase. This was one of the first major reviews of trial data for patients who were treated with a paclitaxel coated device used in peripheral vessels following a meta analysis study of paclitaxel device trials published in December 2018 that showed a mortality safety signal. This was a major discussion during the FDA townhall meeting at the #TCT2019.
News | Drug-Eluting Balloons | October 10, 2019

October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no...

BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019

October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac...

TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-...

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019

October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-...

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...

RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced acute kidney injury (CI-AKI) for patients with kidney disease who undergo interventional cath lab procedures. Results of the 700 patient, randomized, investigator-driven REMEDIAL III Trial presented at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. #TCT19 #TCT2019
News | October 04, 2019

October 4, 2019 – RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced...

Overlay Init